Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Danish Headache Center
22 healthy participants will randomly be allocated to receive PACAP38 infusion followed by glibenclamide or placebo on two different days.
The aim of the study is to investigate the vascular effect of PACAP38 after glibenclamide administration.
Repeated measurements covering the arteria radialis (RA), superficial temporal artery (STA) and middle cerebral artery (MCA) before and after PACAP38 infusion and glibenclamide/placebo administration
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy volunteers of both sexes.
18-60 years.
50-100 kg.
Women of childbearing age must use adequate contraception
You may not be if
A history of serious somatic or psychiatric disease
Migraine or any other type of headache (except episodic tension-type headache less than 5 days per month)
Daily intake of any medication except contraceptives
Clareo Health | The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers
